Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth.

TitlePhosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth.
Publication TypeJournal Article
Year of Publication2010
AuthorsHuang, PH, Miraldi, ER, Xu, AM, Kundukulam, VA, Del Rosario, AM, Flynn, RA, Cavenee, WK, Furnari, FB, White, FM
JournalMol Biosyst
Volume6
Issue7
Pagination1227-37
Date Published2010 Jul
ISSN1742-2051
KeywordsCell Line, Tumor, Cell Proliferation, Enzyme Activation, Gene Regulatory Networks, Glioblastoma, Humans, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Models, Biological, Mutation, Phosphorylation, Phosphotyrosine, Receptor, Epidermal Growth Factor, Signal Transduction, Tyrosine
Abstract

To evaluate the role of individual EGFR phosphorylation sites in activating components of the cellular signaling network we have performed a mass spectrometry-based analysis of the phosphotyrosine network downstream of site-specific EGFRvIII mutants, enabling quantification of network-level effects of site-specific point mutations. Mutation at Y845, Y1068 or Y1148 resulted in diminished receptor phosphorylation, while mutation at Y1173 led to increased phosphorylation on multiple EGFRvIII residues. Altered phosphorylation at the receptor was recapitulated in downstream signaling network activation levels, with Y1173F mutation leading to increased phosphorylation throughout the network. Computational modeling of GBM cell growth as a function of network phosphorylation levels highlights the Erk pathway as crucial for regulating EGFRvIII-driven U87MG GBM cell behavior, with the unexpected finding that Erk1/2 is negatively correlated to GBM cell growth. Genetic manipulation of this pathway supports the model, demonstrating that EGFRvIII-expressing U87MG GBM cells are sensitive to Erk activation levels. Additionally, we developed a model describing glioblastoma cell growth based on a reduced set of phosphoproteins, which represent potential candidates for future development as therapeutic targets for EGFRvIII-positive glioblastoma patients.

DOI10.1039/c001196g
Alternate JournalMol Biosyst
PubMed ID20461251
PubMed Central IDPMC3291333
Grant ListP01 CA095616-10 / CA / NCI NIH HHS / United States
P01-CA95616 / CA / NCI NIH HHS / United States
R01 CA096504-01 / CA / NCI NIH HHS / United States
R01 CA118705-01A2 / CA / NCI NIH HHS / United States
R01-CA096504 / CA / NCI NIH HHS / United States
R01-CA118705 / CA / NCI NIH HHS / United States
U54 CA112967-07 / CA / NCI NIH HHS / United States
U54-CA112967 / CA / NCI NIH HHS / United States